Literature DB >> 33411856

TRK-Fused Gene (TFG), a protein involved in protein secretion pathways, is an essential component of the antiviral innate immune response.

Kashif Aziz Khan1, Alexandre Marineau1, Priscilla Doyon1, Mariana Acevedo1, Étienne Durette1, Anne-Claude Gingras2,3, Marc J Servant1.   

Abstract

Antiviral innate immune response to RNA virus infection is supported by Pattern-Recognition Receptors (PRR) including RIG-I-Like Receptors (RLR), which lead to type I interferons (IFNs) and IFN-stimulated genes (ISG) production. Upon sensing of viral RNA, the E3 ubiquitin ligase TNF Receptor-Associated Factor-3 (TRAF3) is recruited along with its substrate TANK-Binding Kinase (TBK1), to MAVS-containing subcellular compartments, including mitochondria, peroxisomes, and the mitochondria-associated endoplasmic reticulum membrane (MAM). However, the regulation of such events remains largely unresolved. Here, we identify TRK-Fused Gene (TFG), a protein involved in the transport of newly synthesized proteins to the endomembrane system via the Coat Protein complex II (COPII) transport vesicles, as a new TRAF3-interacting protein allowing the efficient recruitment of TRAF3 to MAVS and TBK1 following Sendai virus (SeV) infection. Using siRNA and shRNA approaches, we show that TFG is required for virus-induced TBK1 activation resulting in C-terminal IRF3 phosphorylation and dimerization. We further show that the ability of the TRAF3-TFG complex to engage mTOR following SeV infection allows TBK1 to phosphorylate mTOR on serine 2159, a post-translational modification shown to promote mTORC1 signaling. We demonstrate that the activation of mTORC1 signaling during SeV infection plays a positive role in the expression of Viperin, IRF7 and IFN-induced proteins with tetratricopeptide repeats (IFITs) proteins, and that depleting TFG resulted in a compromised antiviral state. Our study, therefore, identifies TFG as an essential component of the RLR-dependent type I IFN antiviral response.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33411856      PMCID: PMC7790228          DOI: 10.1371/journal.ppat.1009111

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  125 in total

Review 1.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

2.  Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6.

Authors:  Hans Häcker; Vanessa Redecke; Blagoy Blagoev; Irina Kratchmarova; Li-Chung Hsu; Gang G Wang; Mark P Kamps; Eyal Raz; Hermann Wagner; Georg Häcker; Matthias Mann; Michael Karin
Journal:  Nature       Date:  2005-11-23       Impact factor: 49.962

Review 3.  Pathogen recognition by the innate immune system.

Authors:  Himanshu Kumar; Taro Kawai; Shizuo Akira
Journal:  Int Rev Immunol       Date:  2011-02       Impact factor: 5.311

4.  IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.

Authors:  Xiaoduo Xie; Denghong Zhang; Bin Zhao; Min-Kan Lu; Ming You; Gianluigi Condorelli; Cun-Yu Wang; Kun-Liang Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-04       Impact factor: 11.205

5.  Translational control of the innate immune response through IRF-7.

Authors:  Rodney Colina; Mauro Costa-Mattioli; Ryan J O Dowling; Maritza Jaramillo; Lee-Hwa Tai; Caroline J Breitbach; Yvan Martineau; Ola Larsson; Liwei Rong; Yuri V Svitkin; Andrew P Makrigiannis; John C Bell; Nahum Sonenberg
Journal:  Nature       Date:  2008-02-13       Impact factor: 49.962

6.  Negative regulation of RIG-I-mediated antiviral signaling by TRK-fused gene (TFG) protein.

Authors:  Na-Rae Lee; Han-Bo Shin; Hye-In Kim; Myung-Soo Choi; Kyung-Soo Inn
Journal:  Biochem Biophys Res Commun       Date:  2013-06-26       Impact factor: 3.575

7.  Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.

Authors:  Benjamin R tenOever; Sonia Sharma; Wen Zou; Qiang Sun; Nathalie Grandvaux; Ilkka Julkunen; Hiroaki Hemmi; M Yamamoto; Shizuo Akira; Wen-Chen Yeh; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Regulation of two interferon-inducible human genes by interferon, poly(rI).poly(rC) and viruses.

Authors:  M G Wathelet; I M Clauss; J Content; G A Huez
Journal:  Eur J Biochem       Date:  1988-06-01

Review 9.  The IKK-related kinases: from innate immunity to oncogenesis.

Authors:  Jean-François Clément; Sylvain Meloche; Marc J Servant
Journal:  Cell Res       Date:  2008-09       Impact factor: 25.617

10.  The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response.

Authors:  Didier Soulat; Tilmann Bürckstümmer; Sandra Westermayer; Adriana Goncalves; Angela Bauch; Adrijana Stefanovic; Oliver Hantschel; Keiryn L Bennett; Thomas Decker; Giulio Superti-Furga
Journal:  EMBO J       Date:  2008-06-26       Impact factor: 11.598

View more
  3 in total

Review 1.  TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense.

Authors:  Ling Wang; Shunbin Ning
Journal:  Viruses       Date:  2021-02-11       Impact factor: 5.818

2.  TRK-fused gene (TFG) regulates ULK1 stability via TRAF3-mediated ubiquitination and protects macrophages from LPS-induced pyroptosis.

Authors:  Jian-Hong Shi; Chen Ling; Ting-Ting Wang; Li-Nuo Zhang; Wen-Wen Liu; Yan Qin; Ying-Hui Tan; Nai-Peng Cui; Zhi-Yu Ni
Journal:  Cell Death Dis       Date:  2022-01-28       Impact factor: 9.685

3.  Positive Selection Drives the Adaptive Evolution of Mitochondrial Antiviral Signaling (MAVS) Proteins-Mediating Innate Immunity in Mammals.

Authors:  Hafiz Ishfaq Ahmad; Gulnaz Afzal; Muhammad Nouman Iqbal; Muhammad Arslan Iqbal; Borhan Shokrollahi; Muhammad Khalid Mansoor; Jinping Chen
Journal:  Front Vet Sci       Date:  2022-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.